Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial by Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli

Get full text

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma by Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, Vivien Wagner, Elias K Mai, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Omar Nadeem, Adam S Sperling

Get full text

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma by Jan H. Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Thomas Hielscher, Lilan Gatti, Joseph Kauer, Omar Nadeem, Elias K. Mai, Christian S. Michel, Mirco J. Friedrich, David Sedloev, Niels Weinhold, Hartmut Goldschmidt, Klaus Herfarth, Anita Schmitt, Michael Hundemer, Michael Schmitt, Carsten Müller-Tidow, Max Topp, Hermann Einsele, Peter Dreger, Nikhil C. Munshi, Adam S. Sperling, Leo Rasche, Sandra Sauer, Marc S. Raab

Get full text